Global Hospital-Acquired Infection Control Market 2017-2021


◆タイトル:Global Hospital-Acquired Infection Control Market 2017-2021
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD3,500 ⇒換算¥388,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥555,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About Hospital-Acquired Infection Control
HAIs, which are also called nosocomial infections, refer to a collection of conditions that a patient may develop when being treated in hospitals or other healthcare facilities. Modern healthcare settings use multiple devices to treat patients. These can be breeding grounds for microorganisms, which can have adverse effects on patient health. HAIs have caused a significant cost burden on patients and healthcare facilities.

Technavio’s analysts forecast the global hospital-acquired infection control market to grow at a CAGR of 4.81% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global hospital-acquired infection control market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of HAI products.

The market is divided into the following segments based on geography:
• Americas

Technavio’s report, Global Hospital-Acquired Infection Control Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AstraZeneca
• GlaxoSmithKline
• Merck
• Pfizer

[Other prominent vendors]
• 3M
• Abbott Laboratories
• AbbVie
• Advanced Sterilization Products
• Alere
• Bayer
• BD
• bioMérieux
• Cepheid
• Getinge Group
• Hoffmann La-Roche
• Synergy Health
• Xenex

[Market driver]
• Increasing innovative measures to prevent HAIs
• For a full, detailed list, view our report

[Market challenge]
• Emergence of antibiotic resistance
• For a full, detailed list, view our report

[Market trend]
• Emergence of innovative techniques to remove biofilms
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Overview

PART 05: Market landscape
• Overview
• Market size and forecast
• Five forces analysis

PART 06: Segmentation by infection type
• Overview
• SSIs
• Respiratory infections

PART 07: Segmentation by end-user
• Overview
• Hospitals and ICUs
• Outpatient care centers
• Others

PART 08: Segmentation by geography
• Overview
• Americas

PART 09: Decision framework

PART 10: Drivers and challenges
• Market drivers
• Market challenges

PART 11: Market trends
• Emergence of innovative techniques to remove biofilms
• Decrease in regulatory approvals of antibiotics
• Focus on early diagnosis and preventive medicine
• Cost burden of HAIs on patients and hospitals

PART 12: Vendor landscape
• Competitive scenario

PART 13: Key vendor analysis
• AstraZeneca
• GlaxoSmithKline
• Merck
• Pfizer
• Other prominent vendors

PART 14: Appendix
• List of abbreviations


AstraZeneca, GlaxoSmithKline, Merck, Pfizer, 3M, Abbott Laboratories, AbbVie, Advanced Sterilization Products, Alere, Bayer, BD, bioMérieux, Cepheid, Getinge Group, Hoffmann La-Roche, Synergy Health, and Xenex.





★調査レポート[院内感染対策の世界市場2017-2021] (Global Hospital-Acquired Infection Control Market 2017-2021 / IRTNTR13353)販売に関する免責事項
[院内感染対策の世界市場2017-2021] (Global Hospital-Acquired Infection Control Market 2017-2021 / IRTNTR13353)についてEメールでお問い合わせ